Posted On: 09/05/2013 11:51:18 PM
Post# of 72721
$NVDL .004 True Value .02+, Yahoo Target $1.00!
http://www.novadel.com/index.html
52 Week .03+, 3 Year .25+ With 0 Liabilty and Huge News Expect a Nice Return.
SHARE STRUCTURE
91 Million Float,
130 Million O/S
39 Million Held Inside
2 HUGE PATENTED FDA APPROVED PRODUCTS
NitroMist® or ZolpiMist™ intellectual property or licenses
http://www.novadel.com/pipeline/nitromist.htm
http://www.novadel.com/pipeline/zolpimist.htm
NovaDel has two marketed products that have been approved by the FDA: NitroMist® for the treatment of angina, and ZolpiMist™ for the treatment of insomnia.
During the twelve months of 2012, the Company earned royalties from the license of NitroMist and ZolpiMist in the amount of $471,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements
HUGE NEWS RELEASED AUGUST 13/2013
Selling Majority of Assets for $400,000 plus 50,000,000 Shares of SUDA LTD. with an Option for 10,000,000 more at .05 Per Share
http://finance.yahoo.com/news/novadel-announc...00171.html
That's a $2,400,000 - $3,400,000 Deal which our TOP RATE CEO plans to eliminate Liabilites.
Steven B. Ratoff
President & Chief Executive Officer
Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb . Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries.
FULL IN DEPTH LEADERSHIP
http://www.novadel.com/about/leadership.htm
http://www.novadel.com/index.html
52 Week .03+, 3 Year .25+ With 0 Liabilty and Huge News Expect a Nice Return.
SHARE STRUCTURE
91 Million Float,
130 Million O/S
39 Million Held Inside
2 HUGE PATENTED FDA APPROVED PRODUCTS
NitroMist® or ZolpiMist™ intellectual property or licenses
http://www.novadel.com/pipeline/nitromist.htm
http://www.novadel.com/pipeline/zolpimist.htm
NovaDel has two marketed products that have been approved by the FDA: NitroMist® for the treatment of angina, and ZolpiMist™ for the treatment of insomnia.
During the twelve months of 2012, the Company earned royalties from the license of NitroMist and ZolpiMist in the amount of $471,000. The Company also received $200,000 from the sale of NitroMist rights outside the US, Canada and Mexico. Also included in revenue is the recognition of previously received payments under various license agreements
HUGE NEWS RELEASED AUGUST 13/2013
Selling Majority of Assets for $400,000 plus 50,000,000 Shares of SUDA LTD. with an Option for 10,000,000 more at .05 Per Share
http://finance.yahoo.com/news/novadel-announc...00171.html
That's a $2,400,000 - $3,400,000 Deal which our TOP RATE CEO plans to eliminate Liabilites.
Steven B. Ratoff
President & Chief Executive Officer
Senior VP and CFO of the Pharmaceutical Group at Bristol-Myers Squibb . Mr. Ratoff brings extensive credentials to the Company from his distinguished career in the pharmaceutical and consumer goods industries.
FULL IN DEPTH LEADERSHIP
http://www.novadel.com/about/leadership.htm
(0)
(0)Scroll down for more posts ▼
